Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.43 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.42 |
| ▸ | CSNK1D | P48730 | 7/20 | 0.42 |
| ▸ | CSNK1E | P49674 | 7/20 | 0.42 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.41 |
| ▸ | CDK2 | P24941 | 2/20 | 0.41 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.41 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.39 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4915605 | 0.91 | MAPK14 (0.47) | MAPK14TGFBR1ACKR3CSNK1DCSNK1E | |
| SCHEMBL4790528 | 0.88 | MAPK14 (0.50) | MAPK14TGFBR1CSNK1DCSNK1EGRIA1 | |
| SCHEMBL4761883 | 0.87 | MAPK14 (0.47) | MAPK14TGFBR1ACKR3CSNK1DCSNK1E | |
| SCHEMBL4899273 | 0.87 | ACKR3 (0.40) | MAPK14HDAC4TGFBR1ACKR3USP30 | |
| SCHEMBL4828575 | 0.87 | MAPK14 (0.48) | MAPK14TGFBR1ACKR3CSNK1DCSNK1E | |
| SCHEMBL4723030 | 0.85 | MAPK14 (0.53) | MAPK14CSNK1DCSNK1E | |
| SCHEMBL6004413 | 0.85 | MAPK14 (0.56) | MAPK14TGFBR1CSNK1DCSNK1E | |
| SCHEMBL4816024 | 0.85 | MAPK14 (0.47) | MAPK14TGFBR1CSNK1DCSNK1EGRIA1 | |
| SCHEMBL6004538 | 0.84 | MAPK14 (0.52) | MAPK14CSNK1DCSNK1E | |
| SCHEMBL6004854 | 0.80 | MAPK14 (0.46) | MAPK14CSNK1DCSNK1E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060252807-A1 | Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders | KALYPSYS, INC. | 2006-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252807-A1 | Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders | MAPK1, MAP3K1, MAPK4 | MAPK14 26/4885HDAC4 862/4885TGFBR1 572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.